Key result
In a mouse model of myotonic dystrophy type 1, verapamil administration at 200 mg/kg/day rescued weight loss, survival, and muscle function to near wild-type levels.
Why the study?
Does verapamil improve myopathy and survival in a mouse model of myotonic dystrophy type 1?
Does verapamil improve myopathy and survival in a mouse model of myotonic dystrophy type 1?
Pharmacological blockade of the Cav1.1 calcium channel with verapamil rescues severe myopathy and improves survival in a preclinical model of myotonic dystrophy type 1.
Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder caused by an unstable expanded CTG repeat located in the 3'-UTR of the DM1 protein kinase (DMPK) gene. The pathogenic mechanism results in misregulated alternative splicing of hundreds of genes, creating the dilemma of establishing which genes contribute to the mechanism of DM1 skeletal muscle pathology. In this issue of the JCI, Cisco and colleagues systematically tested the combinatorial effects of DM1-relevant mis-splicing patterns in vivo and identified the synergistic effects of mis-spliced calcium and chloride channels as a major contributor to DM1 skeletal muscle impairment. The authors further demonstrated the therapeutic potential for calcium channel modulation to block the synergistic effects and rescue myopathy.
No takes yet. Share an insight, caveat, or question.
Nitschke et al. (2024) conducted an editorial in Myotonic dystrophy type 1 (DM1). Verapamil was evaluated. In a mouse model of myotonic dystrophy type 1, verapamil administration at 200 mg/kg/day rescued weight loss, survival, and muscle function to near wild-type levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: